Fisher Funds Trims Boston Scientific Stock Position

Institutional investor reduces stake in medical device company by over 23%

Apr. 17, 2026 at 10:08am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white macro photograph of the inner workings of a medical device, capturing the industrial might and technical precision of Boston Scientific's operations.An extreme close-up of the complex machinery and components that power Boston Scientific's medical device manufacturing process.Marlborough Today

Fisher Funds Management LTD, an institutional investor, reduced its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 23.3% during the 4th quarter, according to a regulatory filing. The firm now owns 370,577 shares of the medical equipment provider's stock, valued at $35.5 million.

Why it matters

This move by a major institutional investor signals potential concerns about the near-term outlook for Boston Scientific, a leading global medical device company. Investors will be watching to see if other large shareholders follow suit or if this was an isolated portfolio adjustment.

The details

Fisher Funds Management LTD sold 112,639 shares of Boston Scientific during the fourth quarter, reducing its total position to 370,577 shares. The firm cited unspecified factors in its decision to trim the stake in the medical equipment provider.

  • Fisher Funds Management LTD reported the stock sale in a 13F filing for the fourth quarter of 2025.
  • The share sale occurred between October 1 and December 31, 2025.

The players

Fisher Funds Management LTD

An institutional investment firm that manages a portfolio of stocks, including a position in Boston Scientific Corporation.

Boston Scientific Corporation

A global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

This stock sale by a major institutional investor raises questions about the near-term outlook for Boston Scientific, a leading medical device company. Investors will be closely watching to see if this was an isolated portfolio adjustment or the start of a broader shift in sentiment around the stock.